At the last check on Friday, Amneal Pharmaceuticals Inc.’s (NYSE:AMRX) stock was up $0.75, moving up 22.32 percent to $4.11. The average number of shares traded per day over the past five days has been 917,489 shares. 3 times new highs have been achieved over the past 5 days, with a $1.02 gain in that time frame. In the last twenty days, the average volume was 816,342, while in the previous 50 days, it was 1,087,231.
Since last month, AMRX stock rose 38.85%. Shares of the company fell to $2.29 on 07/05/23, the lowest level in the past month. A 52-week high of $3.71 was reached on 08/04/23 after having rallying from a 52-week low of $1.24. Since the beginning of this year, AMRX’s stock price has risen by 106.53% or $2.19, and marked a new high 23 times. However, the stock has increased by 10.78% since its 52-week high.
AMRX stock investors should be aware that Amneal Pharmaceuticals Inc. (AMRX) stock had its last reported insider trading activity 235 days ago on Dec 12. TPG GP A, LLC, the Former 10% Owner of the company, disposed of 3,884,600 shares for $2.34 on Dec 12. It resulted in a $9,095,402 divestment by the insider.
Valuation Metrics
The stock’s beta is 1.34. Besides these, the trailing price-to-sales (P/S) ratio of 0.53, the price-to-book (PB) ratio of 2.12.
Financial Health
In the three months ended March 30, Amneal Pharmaceuticals Inc.’s quick ratio stood at 1.10, while its current ratio was 1.90, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending March 30 was 9.04, and the total debt-to-equity ratio was 9.50. On the profitability front, the trailing twelve-month gross margin is 35.20% percent. In the year ended March 30, EBITDA margin amounted to 19.92%, whereas operating margins totaled -3.70%. Based on annual data, AMRX earned $784.71 million in gross profit and brought in $2.21 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -3.30%. Return on equity (ROE) for the past 12 months was -46.10%.
In Amneal Pharmaceuticals Inc.’s quarter-end financial report for March 30, it reported total debt of $2.56 billion. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. AMRX’s revenue rose 7.65% to $544.88 million during the quarter, while net income inched up to $557.54 million. While analysts expected Amneal Pharmaceuticals Inc. to report $0.1 quarterly earnings, the actual figure was $0.12 per share. During the quarter, the company generated $94.66 million in EBITDA. The liabilities of Amneal Pharmaceuticals Inc. were 3.49 billion at the end of its most recent quarter ended March 30, and its total debt was $2.85 billion. The value of shareholders’ equity is $305.45 million.
Technical Picture
This quick technical analysis looks at Amneal Pharmaceuticals Inc.’s (AMRX) price momentum. With a historical volatility rate of 130.83%, the RSI 9-day stood at 83.04% on 03 August.
With respect to its five-day moving average, the current Amneal Pharmaceuticals Inc. price is up by +32.44% percent or $1.02. At present, AMRX shares trade +33.71% above its 20-day simple moving average and +184.69% percent above its 100-day simple moving average. However, the stock is currently trading approximately +86.00% above its SMA50 and +103.16% above its SMA200.
Stochastic coefficient K was 63.13% and Stochastic coefficient D was 47.37%, while ATR was 0.25. Given the Stochastic reading of 93.36% for the 14-day period, the RSI (14) reading has been calculated as 77.65%. As of today, the MACD Oscillator reading stands at 0.31, while the 14-day reading stands at 0.29.
Analyst Ratings
Amneal Pharmaceuticals Inc. (AMRX) has been rated Overweight by analysts. According to 1 brokerage firm, AMRX is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Amneal Pharmaceuticals Inc. stock as buy, with 3 recommending it as overweight.
With a median target price of $3.50, the current consensus forecast for the stock is $3.00 – $4.00. Based on these forecasts, analysts predict Amneal Pharmaceuticals Inc. (AMRX) will achieve an average price target of $3.50.
